Effective delivery of arsenic trioxide to HPV-positive cervical cancer cells using optimised liposomes: a size and charge study

Akhtar, Anam, Wang, Scarlet Xiaoyan, Ghali, Lucy ORCID logoORCID: https://orcid.org/0000-0003-3410-6615, Bell, Celia M. ORCID logoORCID: https://orcid.org/0000-0002-3270-7081 and Wen, Xuesong ORCID logoORCID: https://orcid.org/0000-0001-6518-8962 (2018) Effective delivery of arsenic trioxide to HPV-positive cervical cancer cells using optimised liposomes: a size and charge study. International Journal of Molecular Sciences, 19 (4) , 1081. pp. 1-14. ISSN 1661-6596 [Article] (doi:10.3390/ijms19041081)

PDF - Published version (with publisher's formatting)
Available under License Creative Commons Attribution 4.0.

Download (4MB) | Preview


Despite the success of arsenic trioxide (ATO) in treating haematological malignancies, its potential to treat solid tumours has not been fully exploited, owing to its dose-limiting toxicity and poor pharmacokinetics. In order to overcome this hurdle, liposomal encapsulation of the drug with different surface charges (neutral, negative, and positive) and sizes (100, 200 and 400 nm) were synthesised and tested on human papilloma virus (HPV)-positive HeLa and HPV-negative HT-3 cervical cancer cell lines. Two epithelial cell lines-human keratinocytes (HK) and human colon cells (CRL-1790)-were used as controls. The synthesised liposomes were tested for their physico-chemical characteristics, drug loading efficiency, and toxicity on the studied cell lines. Neutral liposomes of 100 nm in size were the chosen formulation for delivering ATO into the studied cells, as they showed the least intrinsic cytotoxicity and the highest loading efficiency. The findings demonstrated that the optimised formulation of liposomes was an effective drug delivery method for HPV-infected cervical cancer cells. Furthermore, the toxicity vs. uptake ratio was highest for HeLa cells, while a reduced or minimal toxic effect was observed for non-HPV-infected cervical cancer cells and control cells. These findings may provide a promising therapeutic strategy for effectively managing cervical cancers.

Item Type: Article
Additional Information: This article belongs to the Special Issue Nanotechnology in Drug Delivery
Keywords (uncontrolled): arsenic trioxide (ATO), cervical cancer, drug delivery, human papilloma virus (HPV), liposome
Research Areas: A. > School of Science and Technology > Natural Sciences
Item ID: 24449
Notes on copyright: © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Useful Links:
Depositing User: Jisc Publications Router
Date Deposited: 03 Jul 2018 13:38
Last Modified: 29 Nov 2022 19:58
URI: https://eprints.mdx.ac.uk/id/eprint/24449

Actions (login required)

View Item View Item


Activity Overview
6 month trend
6 month trend

Additional statistics are available via IRStats2.